<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Frontotemporal Dementia - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    
    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Frontotemporal Dementia</span>
        </nav>

        <header class="page-header">
            <h1>Frontotemporal Dementia</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Complex</span>
                
                
                <span class="badge badge-mondo">
                    <a href="https://monarchinitiative.org/disease/MONDO:0017276" target="_blank">
                        MONDO:0017276
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Dementia</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Neurodegenerative Disease</span>
                
            </div>
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
        </div>

        <!-- Subtypes -->
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">TDP-43 Proteinopathy</div>
                
                <div class="item-desc">TAR DNA-binding protein of 43 kDa (TDP-43) is the main ubiquitinated protein in tau-negative frontotemporal lobar degeneration (FTLD-TDP), accounting for over 50% of FTD cases. TDP-43 is typically a nuclear protein, and its aggregation and cytoplasmic translocation are thought to represent major pathogenic steps. The abnormal accumulation leads to neuronal dysfunction and death.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000540" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/19664364" target="_blank">PMID:19664364</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"TDP-43 is typically a nuclear protein, and its aggregation and cytoplasmic translocation are thought to represent major steps in the pathogenesis of FTLD due to TDP-43 proteinopathy (FTLD-TDP)."</div>
                
                
                <div class="evidence-explanation">This confirms that TDP-43 aggregation and mislocalization are central to the pathogenesis of FTLD-TDP, a major subtype of frontotemporal dementia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Tau Proteinopathy</div>
                
                <div class="item-desc">FTLD-tau is characterized by accumulation of hyperphosphorylated tau protein, accounting for approximately 45% of FTD cases. This includes Pick&#39;s disease with characteristic Pick bodies. The tau pathology disrupts microtubule function and causes neuronal degeneration primarily in frontal and temporal regions.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000540" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Frontal and Temporal Lobe Atrophy</div>
                
                <div class="item-desc">Progressive neuronal loss and atrophy predominantly affecting the frontal and temporal lobes, with patterns varying by genetic subtype. MAPT mutations show temporal predominance, while GRN and C9orf72 mutations may show more variable patterns. This structural degeneration underlies the behavioral and language deficits.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000540" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26473392" target="_blank">PMID:26473392</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"MAPT patients were younger than other groups, and showed more frequent behavioural disinhibition, repetitive and stereotyped behaviours, semantic impairment and temporal predominance of atrophy."</div>
                
                
                <div class="evidence-explanation">This demonstrates the genotype-specific patterns of brain atrophy and their relationship to clinical phenotypes in frontotemporal dementia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Neuronal Death</div>
                
                <div class="item-desc">Progressive loss of neurons in frontal and temporal cortices due to protein aggregation toxicity, leading to brain atrophy and functional decline. The neurodegeneration progresses over years to decades, with biomarker changes detectable up to 30 years before symptom onset in genetic cases.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000540" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30711676" target="_blank">PMID:30711676</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We observed that biological changes and intracortical facilitation transmission abnormalities significantly antecede the emergence of clinical symptoms of at least 3 decades."</div>
                
                
                <div class="evidence-explanation">This shows that neurobiological changes underlying neuronal dysfunction begin decades before clinical symptoms in genetic FTD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="graph-warning">
                <strong>Referential integrity issues (4):</strong>
                <ul>
                    
                    <li>Target &#39;Behavioral and Language Changes&#39; (from &#39;TDP-43 Proteinopathy&#39;) not found in named elements</li>
                    
                    <li>Target &#39;Behavioral and Language Changes&#39; (from &#39;Tau Proteinopathy&#39;) not found in named elements</li>
                    
                    <li>Target &#39;Behavioral Variant FTD&#39; (from &#39;Frontal and Temporal Lobe Atrophy&#39;) not found in named elements</li>
                    
                    <li>Target &#39;Primary Progressive Aphasia&#39; (from &#39;Frontal and Temporal Lobe Atrophy&#39;) not found in named elements</li>
                    
                    
                </ul>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    Tau_Proteinopathy[&#34;Tau Proteinopathy&#34;]
    Frontal_and_Temporal_Lobe_Atrophy[&#34;Frontal and Temporal Lobe Atrophy&#34;]
    Behavioral_and_Language_Changes[&#34;Behavioral and Language Changes&#34;]
    Primary_Progressive_Aphasia[&#34;Primary Progressive Aphasia&#34;]
    Neuronal_Death[&#34;Neuronal Death&#34;]
    TDP_43_Proteinopathy[&#34;TDP-43 Proteinopathy&#34;]
    Behavioral_Variant_FTD[&#34;Behavioral Variant FTD&#34;]

    TDP_43_Proteinopathy --&gt; Neuronal_Death
    TDP_43_Proteinopathy -.-&gt; Behavioral_and_Language_Changes
    Tau_Proteinopathy --&gt; Neuronal_Death
    Tau_Proteinopathy -.-&gt; Behavioral_and_Language_Changes
    Frontal_and_Temporal_Lobe_Atrophy -.-&gt; Behavioral_Variant_FTD
    Frontal_and_Temporal_Lobe_Atrophy -.-&gt; Primary_Progressive_Aphasia

    style Tau_Proteinopathy fill:#dbeafe
    style Frontal_and_Temporal_Lobe_Atrophy fill:#dbeafe
    style Behavioral_and_Language_Changes fill:#fee2e2,stroke:#dc2626,stroke-dasharray: 5 5
    style Primary_Progressive_Aphasia fill:#fee2e2,stroke:#dc2626,stroke-dasharray: 5 5
    style Neuronal_Death fill:#dbeafe
    style TDP_43_Proteinopathy fill:#dbeafe
    style Behavioral_Variant_FTD fill:#fee2e2,stroke:#dc2626,stroke-dasharray: 5 5</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Behavioral Changes
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                </div>
                
                <div class="item-desc">Prominent behavioral changes including disinhibition, apathy, loss of empathy, compulsive behaviors, and dietary changes. Particularly characteristic of behavioral variant FTD.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26473392" target="_blank">PMID:26473392</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"MAPT patients were younger than other groups, and showed more frequent behavioural disinhibition, repetitive and stereotyped behaviours, semantic impairment and temporal predominance of atrophy."</div>
                
                
                <div class="evidence-explanation">This confirms that behavioral disinhibition and repetitive stereotyped behaviors are core clinical features of genetic FTD, particularly in MAPT mutations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Aphasia
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002381" target="_blank">
                            HP:0002381
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Progressive language impairment, particularly non-fluent aphasia in GRN mutations and semantic variant primary progressive aphasia. Language deficits may be the presenting feature.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26473392" target="_blank">PMID:26473392</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"GRN patients were older at death and more likely to present with non-fluent aphasia."</div>
                
                
                <div class="evidence-explanation">This demonstrates that non-fluent aphasia is a characteristic presenting feature in patients with GRN mutations causing frontotemporal dementia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Personality Changes
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000751" target="_blank">
                            HP:0000751
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Progressive changes in personality including social inappropriateness, loss of emotional warmth, and altered social cognition. C9orf72 patients may paradoxically appear socially warm despite other behavioral changes.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26473392" target="_blank">PMID:26473392</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"They showed more psychotic symptoms and irrational behaviour, yet were more often reported clinically as socially appropriate and warm."</div>
                
                
                <div class="evidence-explanation">This highlights the complex and sometimes paradoxical personality changes in C9orf72-related FTD, where patients may retain apparent social warmth despite significant behavioral dysfunction.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Dementia
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000726" target="_blank">
                            HP:0000726
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Progressive cognitive decline affecting executive function, social cognition, and behavior, with relatively preserved memory in early stages compared to Alzheimer&#39;s disease.</div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    MAPT
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Mutations cause autosomal dominant FTD with tau pathology)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26473392" target="_blank">PMID:26473392</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"MAPT patients were younger than other groups, and showed more frequent behavioural disinhibition, repetitive and stereotyped behaviours, semantic impairment and temporal predominance of atrophy."</div>
                
                
                <div class="evidence-explanation">This confirms the distinct clinical and anatomical phenotype associated with MAPT mutations in frontotemporal dementia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    GRN
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Mutations cause autosomal dominant FTD with TDP-43 pathology)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26473392" target="_blank">PMID:26473392</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"GRN patients were older at death and more likely to present with non-fluent aphasia."</div>
                
                
                <div class="evidence-explanation">This demonstrates the characteristic clinical presentation of GRN-related FTD with language deficits.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30711676" target="_blank">PMID:30711676</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Presymptomatic carriers of GRN and C9orf72 mutations, the most frequent genetic causes of frontotemporal lobar degeneration, represent the optimal target population for the development of disease-modifying drugs."</div>
                
                
                <div class="evidence-explanation">This confirms GRN as one of the two most common genetic causes of FTD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    C9orf72
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Hexanucleotide repeat expansion causes autosomal dominant FTD, often with ALS)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26473392" target="_blank">PMID:26473392</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"C9orf72 patients alone showed a co-occurrence of ALS. They showed more psychotic symptoms and irrational behaviour, yet were more often reported clinically as socially appropriate and warm."</div>
                
                
                <div class="evidence-explanation">This highlights the distinctive clinical features of C9orf72-related FTD including the frequent association with ALS and unique behavioral profile.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30711676" target="_blank">PMID:30711676</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Presymptomatic carriers of GRN and C9orf72 mutations, the most frequent genetic causes of frontotemporal lobar degeneration, represent the optimal target population for the development of disease-modifying drugs."</div>
                
                
                <div class="evidence-explanation">This confirms C9orf72 as one of the most common genetic causes of FTD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Symptomatic Management
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">No disease-modifying treatments currently available. Management focuses on behavioral symptoms with selective serotonin reuptake inhibitors for compulsive behaviors and agitation, and non-pharmacological approaches including behavioral interventions and caregiver support.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Speech and Language Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Speech therapy interventions for patients with language-variant FTD to maintain communication abilities and quality of life for as long as possible.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Frontotemporal Dementia
description: &gt;
  Frontotemporal Dementia (FTD) is a group of neurodegenerative disorders characterized
  by progressive deterioration of the frontal and temporal lobes of the brain. It presents
  with prominent changes in personality, behavior, and/or language, typically with onset
  before age 65. FTD is associated with abnormal accumulation of tau or TDP-43 proteins.
category: Complex
disease_term:
  preferred_term: frontotemporal dementia
  term:
    id: MONDO:0017276
    label: frontotemporal dementia
parents:
- Dementia
- Neurodegenerative Disease
pathophysiology:
- name: TDP-43 Proteinopathy
  description: &gt;
    TAR DNA-binding protein of 43 kDa (TDP-43) is the main ubiquitinated protein
    in tau-negative frontotemporal lobar degeneration (FTLD-TDP), accounting for
    over 50% of FTD cases. TDP-43 is typically a nuclear protein, and its aggregation
    and cytoplasmic translocation are thought to represent major pathogenic steps.
    The abnormal accumulation leads to neuronal dysfunction and death.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Neuronal Death
  - target: Behavioral and Language Changes
  evidence:
  - reference: PMID:19664364
    supports: SUPPORT
    snippet: TDP-43 is typically a nuclear protein, and its aggregation and cytoplasmic translocation are thought to represent major steps in the pathogenesis of FTLD due to TDP-43 proteinopathy (FTLD-TDP).
    explanation: This confirms that TDP-43 aggregation and mislocalization are central to the pathogenesis of FTLD-TDP, a major subtype of frontotemporal dementia.
- name: Tau Proteinopathy
  description: &gt;
    FTLD-tau is characterized by accumulation of hyperphosphorylated tau protein,
    accounting for approximately 45% of FTD cases. This includes Pick&#39;s disease
    with characteristic Pick bodies. The tau pathology disrupts microtubule function
    and causes neuronal degeneration primarily in frontal and temporal regions.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Neuronal Death
  - target: Behavioral and Language Changes
- name: Frontal and Temporal Lobe Atrophy
  description: &gt;
    Progressive neuronal loss and atrophy predominantly affecting the frontal and
    temporal lobes, with patterns varying by genetic subtype. MAPT mutations show
    temporal predominance, while GRN and C9orf72 mutations may show more variable
    patterns. This structural degeneration underlies the behavioral and language deficits.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Behavioral Variant FTD
  - target: Primary Progressive Aphasia
  evidence:
  - reference: PMID:26473392
    supports: SUPPORT
    snippet: MAPT patients were younger than other groups, and showed more frequent behavioural disinhibition, repetitive and stereotyped behaviours, semantic impairment and temporal predominance of atrophy.
    explanation: This demonstrates the genotype-specific patterns of brain atrophy and their relationship to clinical phenotypes in frontotemporal dementia.
- name: Neuronal Death
  description: &gt;
    Progressive loss of neurons in frontal and temporal cortices due to protein
    aggregation toxicity, leading to brain atrophy and functional decline. The
    neurodegeneration progresses over years to decades, with biomarker changes
    detectable up to 30 years before symptom onset in genetic cases.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:30711676
    supports: SUPPORT
    snippet: We observed that biological changes and intracortical facilitation transmission abnormalities significantly antecede the emergence of clinical symptoms of at least 3 decades.
    explanation: This shows that neurobiological changes underlying neuronal dysfunction begin decades before clinical symptoms in genetic FTD.
phenotypes:
- category: Neurological
  name: Behavioral Changes
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Prominent behavioral changes including disinhibition, apathy, loss of empathy, compulsive behaviors, and dietary changes. Particularly characteristic of behavioral variant FTD.
  evidence:
  - reference: PMID:26473392
    supports: SUPPORT
    snippet: MAPT patients were younger than other groups, and showed more frequent behavioural disinhibition, repetitive and stereotyped behaviours, semantic impairment and temporal predominance of atrophy.
    explanation: This confirms that behavioral disinhibition and repetitive stereotyped behaviors are core clinical features of genetic FTD, particularly in MAPT mutations.
- category: Neurological
  name: Aphasia
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Progressive language impairment, particularly non-fluent aphasia in GRN mutations and semantic variant primary progressive aphasia. Language deficits may be the presenting feature.
  evidence:
  - reference: PMID:26473392
    supports: SUPPORT
    snippet: GRN patients were older at death and more likely to present with non-fluent aphasia.
    explanation: This demonstrates that non-fluent aphasia is a characteristic presenting feature in patients with GRN mutations causing frontotemporal dementia.
  phenotype_term:
    preferred_term: Aphasia
    term:
      id: HP:0002381
      label: Aphasia
- category: Neurological
  name: Personality Changes
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Progressive changes in personality including social inappropriateness, loss of emotional warmth, and altered social cognition. C9orf72 patients may paradoxically appear socially warm despite other behavioral changes.
  evidence:
  - reference: PMID:26473392
    supports: SUPPORT
    snippet: They showed more psychotic symptoms and irrational behaviour, yet were more often reported clinically as socially appropriate and warm.
    explanation: This highlights the complex and sometimes paradoxical personality changes in C9orf72-related FTD, where patients may retain apparent social warmth despite significant behavioral dysfunction.
  phenotype_term:
    preferred_term: Personality changes
    term:
      id: HP:0000751
      label: Personality changes
- category: Neurological
  name: Dementia
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Progressive cognitive decline affecting executive function, social cognition, and behavior, with relatively preserved memory in early stages compared to Alzheimer&#39;s disease.
  phenotype_term:
    preferred_term: Dementia
    term:
      id: HP:0000726
      label: Dementia
genetic:
- name: MAPT
  association: Mutations cause autosomal dominant FTD with tau pathology
  notes: Microtubule-associated protein tau gene on chromosome 17q21. Mutations lead to FTLD-tau pathology. Patients show earlier onset, prominent behavioral disinhibition, stereotyped behaviors, and temporal lobe predominance of atrophy.
  evidence:
  - reference: PMID:26473392
    supports: SUPPORT
    snippet: MAPT patients were younger than other groups, and showed more frequent behavioural disinhibition, repetitive and stereotyped behaviours, semantic impairment and temporal predominance of atrophy.
    explanation: This confirms the distinct clinical and anatomical phenotype associated with MAPT mutations in frontotemporal dementia.
- name: GRN
  association: Mutations cause autosomal dominant FTD with TDP-43 pathology
  notes: Progranulin gene on chromosome 17q21. Haploinsufficiency leads to FTLD-TDP pathology. Patients more likely to present with non-fluent aphasia and are older at symptom onset. GRN and C9orf72 are the most frequent genetic causes.
  evidence:
  - reference: PMID:26473392
    supports: SUPPORT
    snippet: GRN patients were older at death and more likely to present with non-fluent aphasia.
    explanation: This demonstrates the characteristic clinical presentation of GRN-related FTD with language deficits.
  - reference: PMID:30711676
    supports: SUPPORT
    snippet: Presymptomatic carriers of GRN and C9orf72 mutations, the most frequent genetic causes of frontotemporal lobar degeneration, represent the optimal target population for the development of disease-modifying drugs.
    explanation: This confirms GRN as one of the two most common genetic causes of FTD.
- name: C9orf72
  association: Hexanucleotide repeat expansion causes autosomal dominant FTD, often with ALS
  notes: Hexanucleotide (GGGGCC) repeat expansion on chromosome 9p21. Most common genetic cause of FTD. Causes FTLD-TDP pathology. Unique features include co-occurrence with ALS, psychotic symptoms, and paradoxically preserved social warmth.
  evidence:
  - reference: PMID:26473392
    supports: SUPPORT
    snippet: C9orf72 patients alone showed a co-occurrence of ALS. They showed more psychotic symptoms and irrational behaviour, yet were more often reported clinically as socially appropriate and warm.
    explanation: This highlights the distinctive clinical features of C9orf72-related FTD including the frequent association with ALS and unique behavioral profile.
  - reference: PMID:30711676
    supports: SUPPORT
    snippet: Presymptomatic carriers of GRN and C9orf72 mutations, the most frequent genetic causes of frontotemporal lobar degeneration, represent the optimal target population for the development of disease-modifying drugs.
    explanation: This confirms C9orf72 as one of the most common genetic causes of FTD.
treatments:
- name: Symptomatic Management
  description: No disease-modifying treatments currently available. Management focuses on behavioral symptoms with selective serotonin reuptake inhibitors for compulsive behaviors and agitation, and non-pharmacological approaches including behavioral interventions and caregiver support.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: Speech and Language Therapy
  description: Speech therapy interventions for patients with language-variant FTD to maintain communication abilities and quality of life for as long as possible.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Frontotemporal_Dementia.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>